首页 | 本学科首页   官方微博 | 高级检索  
     检索      

血液净化治疗急性肾衰时D-D、t-PA和PAI的改变及临床意义
引用本文:滕琰,薛武军,姜亚卓,项和立,蒋红利.血液净化治疗急性肾衰时D-D、t-PA和PAI的改变及临床意义[J].西安交通大学学报(医学版),2005,26(4):358-360.
作者姓名:滕琰  薛武军  姜亚卓  项和立  蒋红利
作者单位:西安交通大学第一附属医院肾病中心,陕西西安,710061
摘    要:目的研究不同的血液净化方法治疗急性肾衰竭(ARF)时D-二聚体(D-D)、组织型纤溶酶原激活物(t-PA)和纤溶酶原激活物抑制物(PAI)的动态变化及临床意义。方法将37例ARF患者随机分为3组:血液透析(HD)组、血液透析滤过(HDF)组、血液滤过(HF)组,测定治疗前、治疗1、4h后血浆中D-D含量及t-PA、PAI活性,并进行对比分析。对照组为14例健康人。结果①ARF患者D-D含量及PAI活性较对照组明显升高,而t-PA活性明显降低(P<0.05);②HD治疗过程中D-D含量和PAI活性持续升高,t-PA活性持续下降,各个时间段之间均有显著性差异(P<0.05);HDF和HF治疗过程中D-D含量和PAI活性先升高后下降,t-PA活性先下降后升高,各个时间段之间均无显著差异(P>0.05);③治疗4h后,HDF和HF对D-D含量及t-PA、PAI活性的影响与HD相比存在显著性差异(P<0.05)。结论ARF患者体内存在凝血-纤溶系统的紊乱,HD可以加重这种改变。采用HDF或HF治疗可以降低或避免对患者凝血机能的影响,提高临床疗效。

关 键 词:急性肾衰  血液净化  D-二聚体  组织型纤溶酶原激活物  纤溶酶原激活抑制物
文章编号:1671-8259(2005)04-0358-03
收稿时间:2005-04-20
修稿时间:2005-05-18

The changes of D-D, t-PA and PAI in acute renal failure patients during blood purification and its clinical significance
Teng Yan,Xue Wujun,Jiang Yazhuo,Xiang Heli,Jiang Hongli.The changes of D-D, t-PA and PAI in acute renal failure patients during blood purification and its clinical significance[J].Journal of Xi‘an Jiaotong University:Medical Sciences,2005,26(4):358-360.
Authors:Teng Yan  Xue Wujun  Jiang Yazhuo  Xiang Heli  Jiang Hongli
Abstract:Objective To study the dynamic changes and clinical significance of D-D, t-PA and PAI in patients with acute renal failure during the process of different methods of blood purification. Methods Thirty-seven ARF patients were divided into three groups: HD group, HDF group and HF group. Plasma D-D level, t-PA and PAI activity were determined 1 hour, 4 hours before and after treatment. Normal control group consisted of fourteen healthy people. Results ① Plasma D-D level and PAI activity in ARF patients were obviously higher than those in control group, while t-PA activity was lower(P<0.05). ② In HD group, the plasma D-D level and PAI activity increased continuously, while t-PA activity decreased during the therapy process; moreover, there were significant differences in the different therapy time segments(P<0.05). In HDF and HF groups, D-D level and PAI activity increased at first, and then decreased, but the changes of t-PA activity were just opposite to these two. No significant differences were found in the different therapy time segments(P>0.05). ③ After 4 hours of the treatment, compared with HD group, HDF and HF groups had significant difference in plasma D-D level, t-PA and PAI activity(P<0.05). Conclusion There was a disorder of coagulation and fibrinolysis system in ARF patients, and HD can aggravate these changes. HDF or HF may decrease these changes and improve the clinic effects.
Keywords:acute renal failure(ARF)  blood purification  D-dimer(D-D)  tissue-type plasminogen activator((t-PA))  plasminogen activator inhibitor(PAI)
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号